Exact Sciences Corporation develops molecular diagnostic tests designed to prevent, detect, and guide treatment for cancer. Founded in 1995 and headquartered in Madison, Wisconsin, the company operates across more than 120 countries, serving patients and healthcare providers with non-invasive testing solutions. In 2023 alone, more than 4 million people obtained answers about their cancer risk through the company's offerings.
The company's flagship product, Cologuard, is a non-invasive at-home test for colorectal cancer screening that detects both cancer and precancerous conditions. Beyond screening, Exact Sciences provides diagnostic tools spanning cancer prevention, early detection, disease monitoring, and personalized treatment guidance, leveraging advances in molecular diagnostics and at-home testing technology.
With more than 6,500 employees, Exact Sciences has grown from a small startup in Marlborough, Massachusetts to a substantial international organisation. The company has maintained Great Place To Work certification for seven consecutive years, reflecting its focus on supporting its workforce as part of its broader mission to eradicate cancer.
